<DOC>
	<DOCNO>NCT02280109</DOCNO>
	<brief_summary>This open label comparative study tenofovir gel film 10 healthy sexually active woman without active female genital tract disorder . The woman receive single dose formulation - tenofovir gel ( 1 % ; equivalent 40 mg 4ml 's gel ) tenofovir film ( 1.3 % ; 40 mg ) - crossover study design determine pharmacokinetics tenofovir blood , cervical tissue , cervicovaginal fluid ( primary objective ) .</brief_summary>
	<brief_title>Comparison Tenofovir Vaginal Gel Film Formulations</brief_title>
	<detailed_description>This open label comparative study tenofovir gel film 10 healthy sexually active woman without active female genital tract disorder . The woman receive single dose formulation - tenofovir gel ( 1 % ; equivalent 40 mg 4ml 's gel ) tenofovir film ( 1.3 % ; 40 mg ) - crossover study design determine pharmacokinetics tenofovir blood , cervical tissue , cervicovaginal fluid ( primary objective ) . Further , pharmacodynamics assess use cervical tissue ex vivo HIV biopsy challenge , safety determine assessment adverse event follow single dose formulation ( secondary objective ) . The primary endpoint determine concentration tenofovir ( TFV ) metabolite , tenofovir diphosphate ( TFV-DP ) , plasma , tissue homogenate , cervicovaginal fluid . Secondary endpoint determine assess concentration HIV p24 protein explant aliquot sample 21 day post-infection ex vivo , determination Grade 2 high adverse event deem related study product . Research participant receive first tenofovir dose formulation prior follow sampling : - Blood PK plasma collection obtain pre-dose , 0.5 , 1 , 2 , 4 , 5 , 8 12 hour ( Day 0 ) , 24 hour ( Day 1 ) ; 48 hour ( Day 2 ) ; 72 hour ( Day 3 ) ; 168 hour ( Day 7 ) follow tenofovir formulation dosing . - Cervicovaginal fluid sampling , rectal fluid sampling , cervicovaginal biopsy perform ( sequence list ) 5 72 hour dose subject . Cervicovaginal fluid rectal fluid sample also obtain 168 hour . Subjects counsel abstain sexual intercourse insertive vaginal practice 10 day follow administer dose ( 7 day last cervicovaginal sample 72 hour ) . Following safety evaluation visit , research participant return research unit receive second tenofovir dose formulation follow schedule sample collection final safety visit . PK parameter TFV TFV-DP estimate compare gel film formulation . PK parameter include peak concentration ( Cmax ) , area concentration-time curve ( AUC ) , time peak concentration ( Tmax ) , elimination half-life ( t1/2 ) . Tenofovir gel film ex vivo pharmacodynamics also assess analyzed correspondence pharmacokinetics . Visit 1 Visits 2-6 Visit 7 Visits 8-12 Visit 13 - 28 Days Day 0-7 Day 14 Day 28-35 Day 42 These study carry The Johns Hopkins Hospital direction Craig Hendrix , MD , Project PI .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . 18 45 year age ( inclusive ) history receptive vaginal intercourse . 2 . HIV negative within 28 day enrollment 3 . Understand agree local STI reporting requirement . 4 . Able willing provide write informed consent take part study . 5 . Able willing provide adequate information locator purpose . 6 . Availability return study visit , bar unforeseen circumstance . 7 . Availability return second formulation dose time subject 's menstrual cycle first formulation administer , least 10 day menses . 8 . Willing abstain vaginal intercourse insertion anything ( e.g. , drug , vaginal douche , personal lubricant sex toy ) vagina 72 hour study product exposure , 10 day follow study product dosing , comprise total 26 day abstinence , insertion vaginal products/objects participate study . 9 . Willingness partner ( ) use condom ( must contain Nonoxynol9 ) duration study . 10 . Agree participate research study involve drug and/or medical device . 11 . Negative qualitative urine pregnancy test . 12 . Using effective method contraception enrollment . 13 . Willingness remain research unit 12 hour two dose day . 1 . Current sexual partner know participant HIV seropositive . 2 . Individuals , history , engage condomless intercourse HIVinfected partner , partner unknown HIV serostatus , woman exchange sex money , shelter , gift . 3 . Active chlamydia , gonorrhea , syphilis , trichomonas , cervicitis PID within 8 week prior enrollment . 4 . Individuals active hepatitis B infection . 5 . Known history genital HSV ( diagnose either clinical laboratory test ) . 6 . Symptomatic vaginal candidiasis bacterial vaginosis . 7 . Undiagnosed irregular uterine bleed 8 . Pathology female genital tract , 9 . Individuals status post hysterectomy . 10 . History cervicovaginal procedure ( i.e . colposcopy cervical biopsy ) within past 2 month . 11 . History cone biopsy extensive loop electrosurgical excision procedure ( LEEP ) , judgment investigator may affect permeability assessment . 12 . Any known primary secondary urogenital malformation , assessment investigator may interfere intend urine collection PK study . 13 . Use vaginally administer medication within 4 week enrollment 14 . Any active urinary tract infection 15 . By history , subject irregular menstrual cycle . 16 . At screening : ALT AST great 1.5 X site laboratory ULN Hemoglobin le 10.0 g/dL Platelet count le 100,000/mm3 Other safety test outside normal range Findings clinically significant opinion investigator 17 . Estimated creatinine clearance &lt; 60 ml/min base establish nomograms 18 . Recent history ( past 6 month ) injection drug use alcohol use may interfere study . 19 . Unwillingness refrain aspirin NSAIDs product use one week prior one week post study procedure . 20 . Use warfarin heparin . 21 . Use systemic immunomodulatory medication within 4 week enrollment . 22 . Use product contain nonoxynol9 within 4 week enrollment . 23 . Use investigational product within 4 week enrollment . 24 . Any medical condition deem safe participation investigator . 25 . Any individual pregnant actively breast feeding . 26 . Postmenopausal define 12 month amenorrhea .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Tenofovir</keyword>
	<keyword>Healthy Volunteers</keyword>
	<keyword>HIV</keyword>
	<keyword>pharmacokinetics tenofovir gel film</keyword>
</DOC>